Dermatology Clinical Trials
Our founding specialty and deepest bench: embedded research sites inside high-volume dermatology practices, with severity-tagged patient panels and infrastructure ready for topical, oral, injectable, and device protocols, including complex and rare-disease work.
What dermatology capabilities do the sites have?
1M+ active patient database across network dermatology practices, tagged by indication and severity (PASI/BSA bands, Norwood grades).
Dedicated exam rooms for research visits, plus full waiting-room and front-desk integration.
Mohs surgery services at several sites, supporting skin-cancer and procedure-adjacent protocols.
Access-controlled IP room, −20 and −70 freezers, centrifuge and incubator.
EKG, blood pressure, scales, and on-site lab area for safety and PK-light assessments.
Experienced coordinators and an embedded medical monitor for eligibility and safety calls in hours, not queues.
Where are the sites?
- Texas
- New Jersey
- New York
- North Carolina
- Florida
- Connecticut
Types of dermatology studies we current support:
We are supporting phase 2 and 3 studies in moderate-to-severe acne, plaque psoriasis, androgenic alopecia, and lichen sclerosus, to name a few. We can provide pre-feasibility feedback with regard to your specific protocol in 2 business days. See our enrollment estimation process here..
Frequently Asked Questions
Acne (adult and pediatric), plaque psoriasis, atopic dermatitis, androgenetic alopecia, lichen sclerosus, hidradenitis suppurativa, and rare dermatoses, with severity-graded patient tagging in the practice EMRs. If your indication is not listed, ask; the census updates quarterly.
Yes. Sites include access-controlled IP storage, −20 and −70 freezers, centrifuge and incubator capability, and coordinators experienced with biologic administration and cold-chain handling.
Median network startup runs 6.5 weeks, and depending on sponsor needs and document readiness we can activate in as little as two weeks. See the performance board.
Send a protocol synopsis to trials@stryderesearch.com. Preliminary feasibility, from real tagged patient counts, in 48 business hours.